
|Videos|October 5, 2020
Botulinum toxin benefits patients with adult neurogenic lower urinary tract dysfunction
Author(s)Urology Times staff
R. Corey O'Connor, MD, discusses findings from a recent study published in Neurourology and Urodynamics.
Advertisement
In this interview, R. Corey O'Connor, MD, discusses the recent Neurourology and Urodynamics paper, “Intradetrusor botulinum toxin injections (300 units) for the treatment of poorly compliant bladders in patients with adult neurogenic lower urinary tract dysfunction," for which he served as a study author. O'Connor is associate professor of urology at the Medical College of Wisconsin, Milwaukee.
More videos:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: AUA 2026 Update on Prostate Cancer Early Detection, With Badrinath R. Konety, MBBS
2
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
3
Daniel George, MD, on the significance of the capivasertib approval for PTEN-deficient prostate cancer
4
EV plus pembro approval reframes first conversation in MIBC diagnosis
5













